Institutional Investors Bullish on Global Life Sciences Outlook Driven by Three Core Engines

Market analysts believe that the combination of the ongoing interest rate cut cycle, accelerated M&A activity by Big Pharma to bolster pipelines, and the integration of AI into drug discovery will support the medium-to-long-term performance of the healthcare sector.